CRISPR Therapeutics AG

Home » CRISPR Therapeutics AG

Secondary

CRISPR Therapeutics AG

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts.

Symbol

CRSP

Last Closing Price
$23.91

Shares
3,970,000

Effective Date
January 5, 2018

Underwriters
Goldman Sachs, Piper Jaffray, Barclays

To view the prospectus for CRISPR Therapeutics AG, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253